Liver histological changes in untreated chronic hepatitis B patients in indeterminate phase

Figure 1 Flow diagram of patient selection. CHB: Chronic hepatitis B; HCC: Hepatocellular carcinoma.

Figure 2 Liver histological changes in different clinical phases. A: Proportions of chronic hepatitis B patients in different clinical phases; B: The liver histological changes in different clinical phases using liver biopsy. Four phase including including immune tolerant phase, HBeAg-positive immune active phase, inactive phase, and HBeAg-negative immune active phase. ≥ G2 was defined by significant necroinflammation, ≥ S2 defined by significant fibrosis, and ≥ G2/S2 defined by significant histopathological changes.

Figure 3 Age, platelet count, and alanine aminotransferase subgroup liver histopathology comparison in indeterminate patient. A: Distribution of significant liver inflammation (≥ G2), fibrosis (≥ S2), and histological changes (≥ G2/S2) in subgroup of indeterminate patient according to different age, platelet count (PLT), and alanine aminotransferase (ALT) levels; B: Distribution of ≥ G2, ≥ S2, ≥ G2/S2 in different age and PLT groups; C: In different age and ALT groups. ^aP < 0.05, ^bP < 0.001. ALT: Alanine aminotransferase; PLT: Platelet count; ULN: Upper limits of normal.